Jade Therapeutics Company Profile
Jade Therapeutics, founded by Drs. Barbara Wirostko and MaryJane Rafii, is a privately held company headquartered in Salt Lake City, Utah, that develops locally administered, sustained-release formulations of (mostly) already-approved drugs for use in poorly served ophthalmic indications. This approach could enable improved therapeutic outcomes along with increased patient compliance to therapy, decreased frequency of administration and office visits, and avoidance of subsequent surgeries – ultimately resulting in better visual function with enhanced quality of life. Jade believes that its use of proprietary administration formulations of drugs that have already received regulatory approval may significantly decrease development risks and shorten the clinical trial and regulatory approval process. Jade’s lead programs focus on delivering (1) recombinant human growth hormone to help address persistent corneal epithelial defects, and (2) antibiotics to treat bacterial keratitis and corneal ulcers (utilizing funding from a recently awarded National Science Foundation SBIR grant).